Humana Inc. (NYSE:HUM) Shares Sold by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC decreased its stake in Humana Inc. (NYSE:HUM) by 13.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 985 shares of the insurance provider’s stock after selling 155 shares during the period. Valeo Financial Advisors LLC’s holdings in Humana were worth $451,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of HUM. Gradient Investments LLC boosted its stake in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 40 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Humana in the 1st quarter valued at about $28,000. Householder Group Estate & Retirement Specialist LLC purchased a new position in Humana during the 3rd quarter worth approximately $39,000. Nvwm LLC increased its position in Humana by 41.0% during the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after buying an additional 25 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Humana during the fourth quarter worth approximately $55,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of NYSE HUM opened at $312.59 on Monday. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. The company’s 50-day moving average price is $347.21 and its 200 day moving average price is $428.90. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21. The stock has a market cap of $37.71 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 1.83 and a beta of 0.45.

Humana (NYSE:HUM) last released its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The business had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. During the same quarter in the prior year, the company earned $1.62 earnings per share. The firm’s revenue for the quarter was up 17.9% compared to the same quarter last year. As a group, research analysts forecast that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.13%. The ex-dividend date is Wednesday, March 27th. Humana’s payout ratio is currently 17.86%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Bank of America restated a “neutral” rating and set a $342.00 target price (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Truist Financial reaffirmed a “hold” rating and issued a $550.00 target price on shares of Humana in a report on Friday, January 19th. Royal Bank of Canada lowered their price target on Humana from $507.00 to $415.00 and set an “outperform” rating on the stock in a report on Friday, January 26th. Mizuho reduced their price objective on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Finally, Argus downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and an average target price of $465.42.

Insider Buying and Selling

In other news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.29% of the stock is currently owned by company insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.